Skip to main content
Clinical Trials/EUCTR2017-001619-35-BE
EUCTR2017-001619-35-BE
Active, Not Recruiting
Phase 1

Exploratory pathophysiological study in five patients suffering from new-onset lupus nephritis and treated with rituximab as first-line treatment - NL_RTX_FIRST

Cliniques Universitaires Saint-lus, Université catholique de Louvain0 sites5 target enrollmentApril 21, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Cliniques Universitaires Saint-lus, Université catholique de Louvain
Enrollment
5
Status
Active, Not Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 21, 2017
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Cliniques Universitaires Saint-lus, Université catholique de Louvain

Eligibility Criteria

Inclusion Criteria

  • Age \= 15y (except if local ethics committee imposes \= 18y) and \= 65 y
  • systemic lupus erythematosus, according to (ACR/SLICC criteria
  • early untreated Lupus nephritis class III or IV (ISN/RPS 2003\), associated or not to class V
  • uP/C ratio \=1 mg/mg measured in a 24\-h urine collection
  • No immunosuppressive therapy (never)
  • No targeted biological therapy never)
  • No renal failure (eGFR \< 60 mL/min)
  • No Biological and clinical nephrotic syndrome
  • Contraception (any type)
  • Signed informed consent (drafted according to local practice and approuved by the local ethics committee)

Exclusion Criteria

  • Breast\-feeding
  • Renal failure (eGFR \< 60 mL/min)
  • Biological and clinical nephrotic syndrome
  • HIV, HCV, HBV infections
  • Active tuberculosis
  • History of malignancy (except non\-melanoma skin and cervical intraepithelial cervical cancer)
  • Previous targeted biological therapy
  • Intercurrent disease interfering with treatment and/or clinical evaluation

Outcomes

Primary Outcomes

Not specified

Similar Trials